537 research outputs found
Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
No full textReactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia
No full text
Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2 resistant autologous acute myeloid leukaemia blasts
No full textPleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
No full textIntraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia.
No full textClinical and prognostic features of patients with myelodysplastic/myeloproliferative sindrome categorized as unclassified (MDS/MPD-U) by WHO classification.
No full textCoronaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules overexpression?
No full textBody mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.
No full text..
SKIN ADVERSE EVENTS IN CML PATIENTS TREATED WITH IMATINIB: OCCURRENCE OF PECULIAR MANIFESTATIONS AFTER 1 YEAR OF THERAPY
No full text- …
